$LIFE

Ethos Technologies Inc. is providing the below beneficial ownership table to provide updated information regarding the beneficial ownership of shares of the…

Ethos Technologies Inc. (LIFE) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. Ethos Technologies Inc. (the “Company”) is providing the below beneficial ownership table to provide updated information regarding the beneficial ownership of shares of the Company’s Class A common stock, $0.0001 par value (the “Class A common stock”) and

Original reporting
Published Oct 9, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LIFE
Neutral
high confidence
Mentioned
$LIFE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LIFENeutralLow
01

Why it matters

The disclosure informs index providers and investors about voting power distribution, but does not indicate a new transaction or earnings change.

02

Market read

Primarily relevant to index trackers and shareholders monitoring ownership concentration.

03

What to watch

Potential voting power shifts from large holders could influence future corporate actions.

Relevance 4/10Novelty 3/10Timing: today

Background

Ethos Technologies filed an 8‑K to update its beneficial ownership table ahead of the December 2026 Russell index reconstitution.

Company-level read

Ticker impact

$LIFENeutralHigh confidence
Context

SEC Form 8‑K filing discloses updated beneficial ownership table for Ethos Technologies, potentially affecting index inclusion.

Expected impact

likely slight pressure as market prices in the ownership data and Russell index reconstitution risk.

Evidence & confidence

The filing provides new ownership details but no material transaction; impact is limited to index‑related speculation.

Market effects

Minimal; the biotech/tech sector may see slight attention to index composition.

US market only, limited to investors tracking Russell indices.

Low; no broader macro or geopolitical effect.

Counterpoint

If the ownership concentration signals upcoming strategic moves, the stock could see upside.

Key entities

  • Ethos Technologies Inc.

    Issuer of the filing, ticker LIFE.

Related articles

$LIFEMed

JPMorgan downgrades Ethos Technologies stock rating to neutral

JPMorgan downgraded Ethos Technologies (LIFE) to Neutral from Overweight, setting a $37 price target. The stock has surged 99% year-to-date. JPMorgan notes growth potential but cites balanced risk-reward and relative valuation concerns. Ethos reported Q2 2026 revenue of $189.6M, up 113% YoY, and raised full-year guidance to $727M-$731M. Other firms adjusted targets post-results.

$LIFEMed

Ethos (LIFE) Grows Revenue 113% While Margins Quietly Compress

Ethos Technologies (LIFE) reported Q2 revenue growth of 113% to $189.6M, with new policies up 133%. Gross profit margin was 98%, but net income rose only 5% to $19.5M. The company authorized a $100M stock buyback. Q3 revenue guidance is $160M-$164M, and full-year guidance is $727M-$731M. Margins compressed, with GAAP net loss of $146.9M for H1 2026 due to stock-based compensation.

$LIFEMedAI 9/10

Ethos (LIFE) Q2 2026 Earnings Call Transcript

Ethos Technologies (LIFE) reported Q2 2026 revenue of $189.6 million, up 113% Y/Y, with direct revenue $116.5 million (+131%) and third-party revenue $73.1 million (+90%). Adjusted EBITDA was $35.2 million (19% margin). Net income was $19.5 million. Full-year 2026 guidance: revenue $727-$731 million and adjusted EBITDA $119-$123 million. Up to $100 million Class A repurchase authorized.

$LIFEMed

Top SMid Cap Pick: Ethos Technologies Leads Citi’s Rankings

Citi analyst Ronald Josey named Ethos Technologies (LIFE) his top SMID-cap pick after the company’s Q2 results. Activated policies growth accelerated to 133% YoY, with 107,800 net activated policies. Revenue rose to $189.6M (+113% YoY). Ethos raised 2026 revenue guidance to $727M-$731M and adjusted EBITDA to $119M-$123M. Citi lifted its price target to $33 and kept Buy/High Risk.